Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative FOLFOX plus cetuximab versus adjuvant FOLFOX plus cetuximab for resectable colorectal cancer liver metastases
2008-005312-41Phase 2Completed
- Sponsor
- RWTH Aachen University
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by RWTH Aachen University. Primary endpoints: Postoperative complication rate and Disease-free survival. Started Jan 2011; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-005312-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005312-41.